lixisenatide (Adlyxin, Lyxumia)

From Aaushi
Jump to navigation Jump to search

Indications

* in patients with type 2 diabetes & recent acute coronary syndrome, lixisenatide did not significantly affect risk of major cardiovascular events[2]

Dosage

  • start 10 ug QD for 14 days, then increase to 20 ug QD

disposable prefilled syringes

Adverse effects

Mechanism of action

More general terms

References

  1. 1.0 1.1 GLP-1 Agonist Lixisenatide (Adlyxin) Okayed for Type 2 Diabetes in US. Medscape. Jul 28, 2016. http://www.medscape.com/viewarticle/866766
    FDA News Release. Jul 28, 2016 FDA approves Adlyxin to treat type 2 diabetes http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513602.htm
  2. 2.0 2.1 Pfeffer MA, Claggett B, Diaz R et al for the ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015 Dec 3;373(23):2247-57. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26630143
  3. 3.0 3.1 3.2 Adam D Diabetes drug slows development of Parkinson's disease. Nature News. April 3, 2024 https://www.nature.com/articles/d41586-024-00974-0
    Meissner WG et al Trial of Lixisenatide in Early Parkinson's Disease. N Engl J Med 2024;390:1176-1185 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38598572 https://www.nejm.org/doi/full/10.1056/NEJMoa2312323

Database